KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Construction in Progress (2016 - 2022)

Amgen has reported Construction in Progress over the past 14 years, most recently at $1.2 billion for Q4 2022.

  • For Q4 2022, Construction in Progress rose 22.9% year-over-year to $1.2 billion; the TTM value through Dec 2022 reached $1.2 billion, up 22.9%, while the annual FY2022 figure was $1.2 billion, 22.9% up from the prior year.
  • Construction in Progress for Q4 2022 was $1.2 billion at Amgen, up from $987.0 million in the prior quarter.
  • Over five years, Construction in Progress peaked at $1.2 billion in Q4 2022 and troughed at $907.0 million in Q4 2019.
  • A 5-year average of $995.0 million and a median of $953.0 million in 2018 define the central range for Construction in Progress.
  • Biggest five-year swings in Construction in Progress: decreased 4.83% in 2019 and later rose 22.9% in 2022.
  • Year by year, Construction in Progress stood at $953.0 million in 2018, then decreased by 4.83% to $907.0 million in 2019, then grew by 0.88% to $915.0 million in 2020, then grew by 7.87% to $987.0 million in 2021, then rose by 22.9% to $1.2 billion in 2022.
  • Business Quant data shows Construction in Progress for AMGN at $1.2 billion in Q4 2022, $987.0 million in Q4 2021, and $915.0 million in Q4 2020.